Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Suffolk
    4. ›
  4. 11779
    5. ›
  5. INGENIOUS TARGETING LABORATORY INC.

INGENIOUS TARGETING LABORATORY INC.

Headquarter
Company claim

Is this your business?

Get access!

Company Details

Name: INGENIOUS TARGETING LABORATORY INC.
Jurisdiction: New York
Legal type: DOMESTIC BUSINESS CORPORATION
Status: Active
Date of registration: 13 Feb 1998 (27 years ago)
Entity Number: 2228858
ZIP code: 11779
County: Suffolk
Place of Formation: New York
Address: 2200 SMITHTOWN AVE, RONKONKOMA, NY, United States, 11779

Shares Details

Shares issued 200

Share Par Value 0

Type NO PAR VALUE

DOS Process Agent

Name Role Address
THE CORPORATION DOS Process Agent 2200 SMITHTOWN AVE, RONKONKOMA, NY, United States, 11779

Chief Executive Officer

Name Role Address
WEI WENG Chief Executive Officer 2200 SMITHTOWN AVE, RONKONKOMA, NY, United States, 11779

Links between entities

Type:
Headquarter of
Company Number:
0970647
State:
CONNECTICUT
CONNECTICUT profile:
INGENIOUS TARGETING LABORATORY INC. (CT)

U.S. Small Business Administration Profile

Website:
http://www.genetargeting.com/
E-Commerce Website:
http://www.genetargeting.com
Phone Number:
631-468-8534
E-mail Address:
sheiffp@genetargeting.com
Contact Person:
PAUL SHEIFFELE
Ownership and Self-Certifications:
Asian Pacific American, Other Minority Owned, Self-Certified Small Disadvantaged Business
User ID:
P0341551

Unique Entity ID

Unique Entity ID:
KLFLHV967JW4
CAGE Code:
3DC70
UEI Expiration Date:
2026-03-21

Business Information

URL:
http://www.genetargeting.com/
Activation Date:
2025-03-24
Initial Registration Date:
2003-01-28

Commercial and government entity program

CAGE number:
3DC70
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-03-24
CAGE Expiration:
2030-03-24
SAM Expiration:
2026-03-21

Contact Information

POC:
PAUL SHEIFFELE
Corporate URL:
http://www.genetargeting.com/

Form 5500 Series

Employer Identification Number (EIN):
113421143
Plan Year:
2024
Number Of Participants:
39
Sponsors Telephone Number:
6315652080
File:
View File
Plan Year:
2023
Number Of Participants:
39
Sponsors Telephone Number:
6314688530
File:
View File
Plan Year:
2022
Number Of Participants:
40
Sponsors Telephone Number:
6314688530
File:
View File
Plan Year:
2021
Number Of Participants:
43
Sponsors Telephone Number:
6314688530
File:
View File
Plan Year:
2020
Number Of Participants:
46
Sponsors Telephone Number:
6314688530
File:
View File

History

Start date End date Type Value
2008-02-26 2012-03-19 Address LIHTI BLDG STE 106, 25 HEALTH SCIENCES DRIVE, STONY BROOK, NY, 11790, 3350, USA (Type of address: Principal Executive Office)
2008-02-26 2012-03-19 Address LIHTI BLDG STE 106, 25 HEALTH SCIENCES DRIVE, STONY BROOK, NY, 11790, 3350, USA (Type of address: Chief Executive Officer)
2008-02-26 2012-03-19 Address LIHTI BLDG STE 106, 25 HEALTH SCIENCES DRIVE, STONY BROOK, NY, 11790, 3350, USA (Type of address: Service of Process)
2000-03-02 2008-02-26 Address LIHTI BLDG STE 106, 25 E LOOP RD, STONY BROOK, NY, 11790, 3350, USA (Type of address: Chief Executive Officer)
2000-03-02 2008-02-26 Address LIHTI BLDG STE 106, 25 E LOOP RD, STONY BROOK, NY, 11790, 3350, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
140328002019 2014-03-28 BIENNIAL STATEMENT 2014-02-01
120319002418 2012-03-19 BIENNIAL STATEMENT 2012-02-01
100312002040 2010-03-12 BIENNIAL STATEMENT 2010-02-01
080226002144 2008-02-26 BIENNIAL STATEMENT 2008-02-01
060317002555 2006-03-17 BIENNIAL STATEMENT 2006-02-01

USAspending Awards / Contracts

Procurement Instrument Identifier:
75N95024P00501
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
25098.00
Base And Exercised Options Value:
25098.00
Base And All Options Value:
25098.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2024-08-26
Description:
CUSTOM CONDITIONAL GPNMB CDNA CASSETTE KNOCKIN MOUSE MODEL
Naics Code:
115210: SUPPORT ACTIVITIES FOR ANIMAL PRODUCTION
Product Or Service Code:
R416: SUPPORT- PROFESSIONAL: VETERINARY/ANIMAL CARE
Procurement Instrument Identifier:
36C26224P0129
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
18388.00
Base And Exercised Options Value:
18388.00
Base And All Options Value:
18388.00
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2023-11-06
Description:
LIVE MICE
Naics Code:
541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Product Or Service Code:
8820: LIVE ANIMALS, NOT RAISED FOR FOOD
Procurement Instrument Identifier:
75N94023P00811
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
13837.60
Base And Exercised Options Value:
13837.60
Base And All Options Value:
13837.60
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2023-09-11
Description:
KNOCKIN MOUSE ES CELL LINE
Naics Code:
541380: TESTING LABORATORIES AND SERVICES
Product Or Service Code:
Q301: MEDICAL- LABORATORY TESTING

USAspending Awards / Financial Assistance

Date:
2022-08-26
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
RESEARCH AND DEVELOPMENT TO ESTABLISH A SMALL ANIMAL MODEL AS A SIGNIFICANT RESOURCE OF HIGH-VALUE SINGLE-DOMAIN ANTIBODIES - PROJECT SUMMARY GENETICALLY-MODIFIED MOUSE MODELS HAVE PROVEN TO BE ESSENTIAL FOR THE PRODUCTION OF ANTIBODY-RELATED BIOLOGICAL DRUGS (BIOLOGICS). TO DATE, THE MAJORITY OF BIOLOGICS ORIGINATE FROM MOUSE MODELS, AND SMALL ANIMAL MODELS ARE USED NOT ONLY TO GENERATE THE ANTIBODIES, BUT ALSO AS A PLATFORM FOR FURTHER OPTIMIZATION AND TESTING OF THE BIOLOGICS. CAMELID-BASED ANTIBODIES, WHICH HAVE SUPERIOR ANTIGEN BINDING AND PHYSICOCHEMICAL PROPERTIES (STABILITY, HYDROPHILICITY, ETC.) HAVE NOT REALIZED THEIR FULL POTENTIAL, TO THE SAME EXTENT THAT CONVENTIONAL ANTIBODIES HAVE. THIS IS FOUNDED IN THE LOGISTIC AND FINANCIAL HURDLES IMMUNIZATION OF CAMELIDS POSE FOR MONOCLONAL HEAVY-CHAIN ANTIBODY (HCAB) PRODUCTION AND THE FACT THAT IN VITRO TECHNOLOGIES CANNOT FULLY RECAPITULATE THE EXCEPTIONAL NATURAL SELECTION TOWARDS EXTREMELY DIVERSIFIED, HIGH-AFFINITY BINDERS THAT OCCURS IN ANIMALS. IN THIS SBIR PROJECT WE PROPOSE TO DEVELOP GENETIC PLATFORMS IN A MURINE HOST FOR THE DISCOVERY AND DEVELOPMENT OF PARTIALLY HUMANIZED HYBRID HCABS (AND THEIR PRODUCTS). SINCE THEIR DISCOVERY IN THE EARLY 1990S, HCABS HAVE GENERATED PROGRESSIVE INTEREST IN THE BIOTECH, DIAGNOSTIC AND THERAPEUTIC FIELDS DUE TO THEIR INTRINSIC PROPERTIES AND ADAPTABILITY. APART FROM A SMALL SIZE PAIRED WITH ROBUSTNESS AND SUPERIOR ACCESS TO DIFFICULT EPITOPES, HCABS CAN BE EASILY PROCESSED INTO, AND UTILIZED AS, SINGLE DOMAIN BINDING UNITS (VHH) WHILE PRESERVING THEIR AFFINITY TOWARDS ANTIGENS (IN CONTRAST TO CONVENTIONAL ANTIBODIES). THE PROPOSED TARGETED MOUSE MODELS CARRYING AN ENGINEERED IMMUNOGLOBULIN LOCUS WILL POTENTIATE THE PRODUCTION OF HIGH AFFINITY HCABS BY SERVING AS AN ALTERNATIVE, HYBRID AB HOST. IT WILL ALLOW NATURAL, IN VIVO AFFINITY-MATURATION OF ANTIGEN-SPECIFIC HCABS IN A SMALL ANIMAL PLATFORM, ONE AMENABLE TO FURTHER GENETIC MANIPULATION. IT WILL ENABLE LARGER COHORT SIZES THAN THE NATURAL CAMELID HOSTS, AND STREAMLINE HCAB GENERATION, THUS PROVIDING FURTHER POTENTIAL FOR THE DEVELOPMENT OF HCAB AND VHH DOMAINS FOR DOWNSTREAM APPLICATIONS. IN OUR AIM 1, WE FOCUS ON HONING AND CHARACTERIZING OUR HYBRID CAMELID IMMUNOGLOBULIN LOCUS BY ADDING MORE CAMELID VHHS AND INTRODUCING MODIFIED HUMAN VHS INTO THE LOCUS WHILE ALSO EVALUATING B-CELL DEVELOPMENT AND ANTIBODY AFFININTY AND DIVERSITY. IN AIM 2, OUR FOCUS IS TO BENCHMARK THE THE REPERTOIRE AND EFFICIENCY OF THE AB RESPONSE WITH COMPETING TECHNOLOGIES BY USING DISEASE-RELEVANT, DIFFICULT ANTIGENS AND PROGRESS PROMISING HITS TO HYBRIDOMA DEVELOPMENT AND LARGER SCALE ANTIBODY PRODUCTION. IN ACCOMPLISHING THESE MILESTONE BASED AIMS, WE WILL BE ABLE TO DEVELOP OUR BUSINESS AND BEGIN LICENSING OF THE PLATFORMS TO INDIVIDUAL LABS AND ESTABLISHED PHARMACEUTICAL COMPANIES TO SUPPORT DISCOVERY OF NOVEL ANTIBODIES FOR HIGH-VALUE TARGETS.
Obligated Amount:
2990687.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-03-12
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
308535.00
Total Face Value Of Loan:
308535.00
Date:
2020-12-30
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
HUMANIZATION OF ACE2 AND ASSOCIATED PRIMING PROTEASES IN NEW MOUSE MODELS FOR DOWNSTREAM DISEASE AND THERAPY INVESTIGATIONS OF COVID-19 - WITH THE INITIAL WAVE OF ZOONOTIC TRANSMISSION FIRMLY ESTABLISHED IN THE HUMAN POPULATION WORLDWIDE, SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS 2 (SARS-COV-2) POSES AN EMINENT THREAT TO INDIVIDUALS, HEALTH CARE SYSTEMS AND SOCIETIES. VARIOUS DEGREES OF DISEASE SEVERITY (FROM ASYMPTOMATIC TO LETHAL) COMBINED WITH CHALLENGING INFECTION METRICS IN THE ABSENCE OF WIDESPREAD TESTING COVERAGE, AS WELL AS LACK OF ESTABLISHED VACCINATION AND TREATMENT OPTIONS HAVE TRIGGERED MASSIVE AND URGENT BIOMEDICAL EFFORTS TO COUNTER THE ASSOCIATED HUMAN DISEASE THAT IS COVID-19. FOUNDED IN THE COMPLEXITIES OF VIRUS/HOST INTERACTIONS, IT IS IMPERATIVE TO UTILIZE EXPERIMENTAL INFECTIONS WITH VIRUS OR VIRAL MATERIAL IN TRANSLATIONAL PLATFORMS WITH A FOCUS ON VIRAL AND/OR HOST MODELING IN ORDER TO ESTABLISH PREVENTIVE AS WELL AS CONTROL STRATEGIES. IN THIS EXPERIMENTAL SETTING, ANIMAL MODELS PLAY A CENTRAL ROLE AS IN VIVO HOSTS FOR EVALUATION PURPOSES OF ANTIVIRAL DRUGS, IMMUNOTHERAPY AND VACCINES FOREMOST IN PRECLINICAL, BUT ALSO IN PARALLEL-TO-CLINICAL, STUDIES. A SINGLE TYPE OF ORGANISM, EITHER WILDTYPE OR GENETICALLY-MODIFIED, WILL HOWEVER LIKELY NOT BE SUFFICIENT FOR STUDIES OF ALL RELEVANT PHYSIOLOGICAL MECHANISMS. IN THIS PROJECT, WE PROPOSE REVERSE GENETIC DESIGNS IN THE MOUSE BY INTRODUCING GENETICALLY HUMANIZED COMPONENTS ON LARGE AND MEDIUM SCALES, ENABLING VIRAL BINDING AND CELLULAR INFECTION WITH THE AIM TO MIMIC HUMAN COVID-19 DISEASE SUSCEPTIBILITY DURING EARLY STAGES OF THE SARS-COV-2 REPLICATION CYCLE. RODENT SPECIES, ALTHOUGH FAVORABLE AS SMALL ANIMAL RESEARCH OBJECTS, ARE GENERALLY REFRACTORY TO DISPLAYING SARS AND THE COVID-19 PATHOLOGY UPON SIMPLE INFECTION. ONE WAY TO ADDRESS THIS SPECIES BOUNDARY SO FAR WAS TO CREATE RANDOM TRANSGENIC MOUSE LINES CARRYING SMALL-SCALE PARTIALLY HUMANIZED GENE EXPRESSION UNITS FOR THE HUMAN ACE2 RECEPTOR. THESE MODELS, HOWEVER, DISPLAY PARTIAL PHENOTYPES CHARACTERIZED BY: (A) NO TERMINAL-LUNG OUTCOMES, (B) UNDESIRED REPLICATION IN THE BRAIN AND (C) LACK OF MULTI- ORGAN FAILURE UPON INFECTION (EXEMPLIFIED BY SARS-COV, WITH SIMILAR OUTCOMES EXPECTED FOR SARS-COV-2). IN ORDER TO ENABLE A DISTINCT LUNG AND OTHER HUMAN PHENOTYPES, WE HYPOTHESIZE THAT EXTENDED GENOMIC HUMANIZATION IN THE FORM OF THE HUMAN ACE2 RECEPTOR ALONE (SEE SPEC. AIM 1) OR IN COMBINATION WITH LUNG- SPECIFIC HUMAN COFACTORS, I.E., TMPRSS2/FURIN (SEE SPEC. AIM 2) BASED ON THEIR HUMAN-LIKE EXPRESSION (VERIFIED IN SPEC. AIM 3) WILL THUS IMPROVE VIRAL INFECTION AND TISSUE TROPISM MEASURED BY TIMELY PROGRESSION OF VIRAL TITERS IN DIFFERENT ORGANS (IN SPEC. AIM 4). FLUORESCENT REPORTING AS WELL AS SITE-SPECIFIC RECOMBINATION WILL BE ENABLED IN AN ALTERNATIVE CRE-RECOMBINASE FUSION MODEL OF ACE2, WHILE INTRINSIC FEATURES OF THE TMPRSS2/FURIN MODEL WILL PROVIDE A FLUORESCENT SIGNAL UPON EXPRESSION. OUR BROAD SARS/COVID-19 MOUSE MODEL PLATFORM UTILITY (CONSISTING OF THREE INDIVIDUAL MODELS AT THE PHASE I STAGE) WILL SIGNIFICANTLY SUPPORT CROSS- SPECIES TRANSLATIONAL INVESTIGATIONS INTO THE DEVELOPMENT OF DISEASE AND THE TESTING OF INTERVENTION MEASURES BY SPECIALISTS IN THE BIOMEDICAL FIELD THUS, ADDRESSING THEIR SHORT-TERM AND LONG-TERM RESEARCH NEEDS.
Obligated Amount:
589914.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-05-02
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
346044.00
Total Face Value Of Loan:
346044.00
Date:
2020-04-29
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
293000.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
78577468
Mark:
IN THE FIELD OF MICE ONE COMPANY STANDS OUT
Status:
CANCELLED - SECTION 8
Mark Type:
SERVICE MARK
Application Filing Date:
2005-03-01
Mark Drawing Type:
Illustration: Drawing or design which also includes word(s)/letter(s)/number(s)
Mark Literal Elements:
IN THE FIELD OF MICE ONE COMPANY STANDS OUT
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Genetic Engineering of Mouse Models; biological cloning services related to genetically engineered mouse models
First Use:
2004-04-20
International Classes:
042 - Primary Class
Class Status:
Sec. 8 – Entire Registration

Paycheck Protection Program

Jobs Reported:
24
Initial Approval Amount:
$308,535
Date Approved:
2021-03-12
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$308,535
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
$311,365.47
Servicing Lender:
JPMorgan Chase Bank, National Association
Use of Proceeds:
Payroll: $308,533
Utilities: $1
Jobs Reported:
29
Initial Approval Amount:
$346,044
Date Approved:
2020-05-01
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$346,044
Race:
Unanswered
Ethnicity:
Not Hispanic or Latino
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
$349,256.25
Servicing Lender:
JPMorgan Chase Bank, National Association
Use of Proceeds:
Payroll: $303,334.39
Utilities: $14,329.85
Rent: $17,000
Healthcare: $11379.76

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

THE CORPORATION

ARSHIA DESIGNS INC. AAA VACUUM CORP. ATLANTICA TELECOM, INC. MISTY SPORTSWEAR, INC. FAT JAMS ELECTRONICS INC. CROQUEMBOUCHE, INC. LONG BEACH PEDIATRIC GROUP, P.C. LAW OFFICES OF JOSEPH A. GRECO, P.C. TEREZ, INC. 732 CINNAMON BEACH INC.

Related by address

No related companies by address

Date of last update: 31 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated